ADVERTISEMENT
Scott Tykodi, MD, PhD, Discusses Gene Expression Analysis and Mutational Profiling in KEYNOTE-427 Trial for RCC
07/10/2020
Dr Tykodi, University of Washington, Fred Hutchinson Cancer Research Center, Seattle, WA, shares data analyses of cohort A from the KEYNOTE-427 trial on first-line pembrolizumab for clear cell renal cell carcinoma, presented in two abstracts at the virtual 2020 ASCO Annual Meeting.
Advertisement
Advertisement
Advertisement
Advertisement
Advertisement
Advertisement
Advertisement
Advertisement
Advertisement
Advertisement
Advertisement
Visit the OLN Excellence Forums
Advertisement
Advertisement
Advertisement